Document is current
Any future updates will be listed below
-
Authors
Zhang, Li
Zhou, Naihui
Wu, Zhouwei
Chen, Xuejun
Zhu, Huilan
Li, Shanshan
Han, Jianwen
Miao, Guoying
Wu, Liming
Zhu, Rongfei
Lu, Jianyun
Zheng, Yue
Jiang, Xian
Cao, Xianwei
Yu, Dehou
Zhang, Siping
Ding, Yangfeng
Man, Xiaoyong
Cui, Yong
Li, Ying
Dou, Xia
Gao, Xinghua https://orcid.org/0000-0001-8809-8564
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 27 September 2025
Accepted: 8 January 2026
First Online: 11 February 2026
Declarations
:
: Li Zhang, Naihui Zhou, Zhouwei Wu, Xuejun Chen, Huilan Zhu, Shanshan Li, Jianwen Han, Guoying Miao, Liming Wu, Rongfei Zhu, Jianyun Lu, Yue Zheng, Xian Jiang, Xianwei Cao, Dehou Yu, Siping Zhang, Yangfeng Ding, Xiaoyong Man, Yong Cui, Ying Li, Xia Dou, and Xinghua Gao declare that they have no competing interests to disclose.
: The study was conducted in accordance with all the ethical principles outlined in the latest World Medical Association Declaration of Helsinki, Good Pharmacoepidemiology Practices, and adhered to applicable legal and regulatory requirements. The study, study protocol, informed consent, and other related documents were reviewed and approved by the institutional review boards/independent ethics committees of all participating study sites, either verbally or through documented approval (Table ). Master approval was granted by the Ethics Committee of Medical Science Research of the First Affiliated Hospital of China Medical University (reference number Scientific Research Ethics Review [2023] No. 359). All patients provided written informed consent before performing any investigational activity.
